Keith A Wesnes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4549429/publications.pdf

Version: 2024-02-01

270 papers 17,919 citations

7096 78 h-index 123 g-index

295 all docs

295 docs citations

times ranked

295

15467 citing authors

#	Article	IF	CITATIONS
1	The Neurocognitive Effects of Bacopa monnieri and Cognitive Training on Markers of Brain Microstructure in Healthy Older Adults. Frontiers in Aging Neuroscience, 2021, 13, 638109.	3.4	3
2	Cognitive Function in Adults with Enduring Anorexia Nervosa. Nutrients, 2021, 13, 859.	4.1	12
3	Tea consumption and measures of attention and psychomotor speed in the very old: the Newcastle 85+ longitudinal study. BMC Nutrition, 2020, 6, 57.	1.6	4
4	Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. Frontiers in Neurology, 2020, 11, 916.	2.4	8
5	Cognitive profiles in obstructive sleep apnea: a cluster analysis in sleep clinic and community samples. Journal of Clinical Sleep Medicine, 2020, 16, 1493-1505.	2.6	11
6	FLAME: A computerized neuropsychological composite for trials in early dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12098.	2.4	13
7	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 823-834.	1.2	144
8	CoQ10 and Cognition a Review and Study Protocol for a 90-Day Randomized Controlled Trial Investigating the Cognitive Effects of Ubiquinol in the Healthy Elderly. Frontiers in Aging Neuroscience, 2019, 11, 103.	3.4	14
9	D-Cycloserine Improves Difficult Discriminations in a Pattern Separation Task in Alzheimer's Disease Patients with Dementia. Journal of Alzheimer's Disease, 2019, 69, 377-383.	2.6	8
10	The relationship between the frequency of numberâ€puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. International Journal of Geriatric Psychiatry, 2019, 34, 932-940.	2.7	10
11	An online investigation of the relationship between the frequency of word puzzle use and cognitive function in a large sample of older adults. International Journal of Geriatric Psychiatry, 2019, 34, 921-931.	2.7	22
12	Investigating the relationship between age of onset of depressive disorder and cognitive function. International Journal of Geriatric Psychiatry, 2019, 34, 38-46.	2.7	26
13	The impact of blackcurrant juice on attention, mood and brain wave spectral activity in young healthy volunteers. Nutritional Neuroscience, 2019, 22, 596-606.	3.1	23
14	Impaired verbal episodic memory in healthy older adults is marked by increased F 2 -Isoprostanes. Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 129, 32-37.	2.2	15
15	Spearmint Extract Improves Working Memory in Men and Women with Age-Associated Memory Impairment. Journal of Alternative and Complementary Medicine, 2018, 24, 37-47.	2.1	34
16	The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function. British Journal of Clinical Pharmacology, 2018, 84, 1535-1543.	2.4	13
17	Effects of aging and depression on mnemonic discrimination ability. Aging, Neuropsychology, and Cognition, 2018, 25, 464-483.	1.3	12
18	Longitudinal changes in global and domain specific cognitive function in the veryâ€old: findings from the Newcastle 85+ Study. International Journal of Geriatric Psychiatry, 2018, 33, 298-306.	2.7	6

#	Article	IF	CITATIONS
19	Online assessment of risk factors for dementia and cognitive function in healthy adults. International Journal of Geriatric Psychiatry, 2018, 33, e286-e293.	2.7	32
20	A randomised double-blind placebo-controlled pilot trial of a combined extract of sage, rosemary and melissa, traditional herbal medicines, on the enhancement of memory in normal healthy subjects, including influence of age. Phytomedicine, 2018, 39, 42-48.	5. 3	38
21	Poor cognitive ageing: Vulnerabilities, mechanisms and the impact of nutritional interventions. Ageing Research Reviews, 2018, 42, 40-55.	10.9	136
22	P3â€554: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATIONâ€BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY. Alzheimer's and Dementia, 2018, 14, P1335.	00.8	2
23	P1â€523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBI) TOTAL SCOI AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS. Alzheimer's and Dementia, 2018, 14, P532.	₹ _{0.8}	0
24	P1â€151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P335.	0.8	O
25	P2â€483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER. Alzheimer's and Dementia, 2018, 14, P914.	0.8	0
26	P1â€658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS. Alzheimer's and Dementia, 2018, 14, P595.	0.8	1
27	The Cognitive Ageing, Nutrition and Neurogenesis (CANN) trial: Design and progress. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 591-601.	3.7	9
28	Utility, reliability, sensitivity and validity of an online test system designed to monitor changes in cognitive function in clinical trials. International Journal of Geriatric Psychiatry, 2017, 32, e83-e92.	2.7	46
29	Effects of the Red Bull energy drink on cognitive function and mood in healthy young volunteers. Journal of Psychopharmacology, 2017, 31, 211-221.	4.0	25
30	Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments. International Clinical Psychopharmacology, 2017, 32, 72-79.	1.7	10
31	Tolerability of ORMâ€12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 1-9.	3.7	17
32	Does attentional dysfunction and thalamic atrophy predict decline in dementia with Lewy bodies?. Parkinsonism and Related Disorders, 2017, 45, 69-74.	2.2	20
33	Homocysteine, Tryptophan, and Cognition in the Very Old. Journal of the American Medical Directors Association, 2017, 18, 895-896.	2.5	0
34	One-Carbon Metabolism Biomarkers and Cognitive Decline in the Very Old: The Newcastle 85+ Study. Journal of the American Medical Directors Association, 2017, 18, 806.e19-806.e27.	2.5	18
35	Nutrition for the ageing brain: Towards evidence for an optimal diet. Ageing Research Reviews, 2017, 35, 222-240.	10.9	161
36	Predicting Risk of Cognitive Decline in Very Old Adults Using Three Models: The Framingham Stroke Risk Profile; the Cardiovascular Risk Factors, Aging, and Dementia Model; and Oxiâ€Inflammatory Biomarkers. Journal of the American Geriatrics Society, 2017, 65, 381-389.	2.6	34

#	Article	IF	CITATIONS
37	[P2–581]: THE RELATIONSHIP BETWEEN THE FREQUENCY OF WORD PUZZLE USE AND COGNITIVE FUNCTION IN A LARGE SAMPLE OF ADULTS AGED 50 TO 96 YEARS. Alzheimer's and Dementia, 2017, 13, P869.	0.8	O
38	[P3–582]: CAN INCREASING THE DIFFICULTY OFÂAÂNEUROGENESISâ€SENSITIVE TASK ENHANCE ITS SENSITIVI DETECTING AGEâ€RELATED DECLINES IN VOLUNTEERS AGED 50 TO 96?. Alzheimer's and Dementia, 2017, 13, P1204.	TY TO 0.8	0
39	[P1–599]: ONLINE COGNITIVE TRAINING INCREASES NEUROGENESIS AND IMPROVES COGNITIVE PERFORMANCE IN ADULTS OVER 50. Alzheimer's and Dementia, 2017, 13, P525.	0.8	O
40	[P1–614]: THE ASSOCIATION BETWEEN COGNITIVE FUNCTION AND ACTIVITIES OF DAILY LIVING IN HEALTHY ADULTS AGED 50 AND OVER. Alzheimer's and Dementia, 2017, 13, P532.	0.8	0
41	[P3–563]: RISK FACTORS FOR DEMENTIA AND COGNITIVE FUNCTION IN HEALTHY ADULTS. Alzheimer's and Dementia, 2017, 13, P1194.	0.8	O
42	Current Progress and Future Potential in the Evaluation and Treatment of Age-Related Cognitive Declines. , 2017, , .		0
43	Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum. Innovations in Clinical Neuroscience, 2017, 14, 30-39.	0.1	6
44	Hearing loss and cognition in the Busselton Baby Boomer cohort: An epidemiological study. Laryngoscope, 2016, 126, 2367-2375.	2.0	27
45	Singleâ€Dose Interaction Study of the Arginine Vasopressin Type 1 <scp>B</scp> Receptor Antagonist <scp>ABT</scp> â€436 and Alcohol in Moderate Alcohol Drinkers. Alcoholism: Clinical and Experimental Research, 2016, 40, 838-845.	2.4	16
46	Differences in memory function between 5-HT1A receptor genotypes in patients with major depressive disorder. CNS Spectrums, 2016, 21, 379-384.	1.2	12
47	Relationships Among Cognitive Function and Cerebral Blood Flow, Oxidative Stress, and Inflammation in Older Heart Failure Patients. Journal of Cardiac Failure, 2016, 22, 548-559.	1.7	30
48	The effect of desvenlafaxine on cognitive functioning in employed outpatients with major depressive disorder: a substudy of a randomized, double-blind, placebo-controlled trial. Journal of Psychopharmacology, 2016, 30, 559-567.	4.0	11
49	Cognitive effects of adjunctive perampanel for partialâ€onset seizures: A randomized trial. Epilepsia, 2016, 57, 243-251.	5.1	85
50	Norms for healthy adults aged 18–87 years for the Cognitive Drug Research System: An automated set of tests of attention, information processing and memory for use in clinical trials. Journal of Psychopharmacology, 2016, 30, 263-272.	4.0	14
51	Acute consumption of Peppermint and Chamomile teas produce contrasting effects on cognition and mood in healthy young adults. Plant Science Today, 2016, 3, 327.	0.7	5
52	Does Self-Efficacy Affect Cognitive Performance in Persons with Clinically Isolated Syndrome and Early Relapsing Remitting Multiple Sclerosis?. Multiple Sclerosis International, 2015, 2015, 1-8.	0.8	13
53	Improved working memory performance following administration of a single dose of American ginseng (<scp><i>Panax quinquefolius</i> L.</scp>) to healthy middleâ€age adults. Human Psychopharmacology, 2015, 30, 108-122.	1.5	41
54	Is There an Association Between Metabolic Syndrome and Cognitive Function in Very Old Adults? The Newcastle 85+ Study. Journal of the American Geriatrics Society, 2015, 63, 667-675.	2.6	37

#	Article	IF	CITATIONS
55	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 103-111.	2.4	191
56	Serum 25â€hydroxyvitamin <scp>D</scp> and cognitive decline in the very old: the <scp>N</scp> ewcastle 85+ <scp>S</scp> tudy. European Journal of Neurology, 2015, 22, 106.	3.3	49
57	Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. International Journal of Geriatric Psychiatry, 2015, 30, 46-54.	2.7	67
58	Relationship between Working Hours and Power of Attention, Memory, Fatigue, Depression and Self-Efficacy One Year after Diagnosis of Clinically Isolated Syndrome and Relapsing Remitting Multiple Sclerosis. PLoS ONE, 2014, 9, e96444.	2.5	34
59	Characterizing mild cognitive impairment in incident Parkinson disease. Neurology, 2014, 82, 308-316.	1.1	359
60	Criteria for validation and selection of cognitive tests for investigating the effects of foods and nutrients. Nutrition Reviews, 2014, 72, 162-179.	5.8	54
61	Atomoxetine for attention deficits following traumatic brain injury: Results from a randomized controlled trial. Brain Injury, 2014, 28, 1514-1522.	1.2	25
62	Functional Living in Older Adults With Type 2 Diabetes. Journal of Aging and Health, 2014, 26, 841-859.	1.7	19
63	Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: the case for equal opportunity. Alzheimer's Research and Therapy, 2014, 6, 58.	6.2	12
64	Performance on a pattern separation task by Alzheimer's patients shows possible links between disrupted dentate gyrus activity and apolipoprotein E â^4 status and cerebrospinal fluid amyloid-β42 levels. Alzheimer's Research and Therapy, 2014, 6, 20.	6.2	48
65	The role of human cognitive neuroscience in drug discovery for the dementias. Current Opinion in Pharmacology, 2014, 14, 62-73.	3.5	8
66	Effects of nicotine withdrawal on cognition in a clinical trial setting. Psychopharmacology, 2013, 229, 133-140.	3.1	23
67	Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia. Schizophrenia Research, 2013, 150, 328-333.	2.0	46
68	An evaluation of the cognitive and mood effects of an energy shot over a 6h period in volunteers. A randomized, double-blind, placebo controlled, cross-over study. Appetite, 2013, 67, 105-113.	3.7	25
69	Cocoa polyphenols enhance positive mood states but not cognitive performance: a randomized, placebo-controlled trial. Journal of Psychopharmacology, 2013, 27, 451-458.	4.0	120
70	Modulation of neural activation following treatment of hepatic encephalopathy. Neurology, 2013, 80, 1041-1047.	1.1	22
71	Examining the cognitive effects of a special extract of Bacopa monniera (CDRI08: Keenmnd): A review of ten years of research at Swinburne University. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, 254.	2.1	21
72	Natural Substances as Treatments for Age-Related Cognitive Declines. , 2013, , 3-16.		0

#	Article	IF	Citations
73	Analysis of Neuron-Specific Enolase and S100B as Biomarkers of Cognitive Decline Following Surgery in Older People. Dementia and Geriatric Cognitive Disorders, 2012, 34, 307-311.	1.5	11
74	Short-Term Study on the Effects of Rosemary on Cognitive Function in an Elderly Population. Journal of Medicinal Food, 2012, 15, 10-17.	1.5	7 5
75	The cognitive profile of type 1 Gaucher disease patients. Journal of Inherited Metabolic Disease, 2012, 35, 1093-1099.	3 . 6	17
76	The effects of 90-day supplementation with the Omega-3 essential fatty acid docosahexaenoic acid (DHA) on cognitive function and visual acuity in a healthy aging population. Neurobiology of Aging, 2012, 33, 824.e1-824.e3.	3.1	68
77	The effect of high lactose–isomaltulose on cognitive performance of young children. A double blind cross-over design study. Appetite, 2012, 58, 81-87.	3.7	20
78	Acute ingestion of different macronutrients differentially enhances aspects of memory and attention in healthy young adults. Biological Psychology, 2012, 89, 477-486.	2.2	42
79	Relationship Between Cognition, Magnetic Resonance White Matter Hyperintensities, and Cardiovascular Autonomic Changes in Late-Life Depression. American Journal of Geriatric Psychiatry, 2012, 20, 691-699.	1.2	43
80	Breakfast is associated with enhanced cognitive function in schoolchildren. An internet based study. Appetite, 2012, 59, 646-649.	3.7	49
81	The acute effects of 3,4-methylenedioxymethamphetamine and d-methamphetamine on human cognitive functioning. Psychopharmacology, 2012, 220, 799-807.	3.1	20
82	Steady state visually evoked potential (SSVEP) topography changes associated with cocoa flavanol consumption. Physiology and Behavior, 2012, 105, 948-957.	2.1	72
83	A randomized controlled trial investigating the effect of Pycnogenol and BacopaCDRI08 herbal medicines on cognitive, cardiovascular, and biochemical functioning in cognitively healthy elderly people: the Australian Research Council Longevity Intervention (ARCLI) study protocol (ANZCTR12611000487910). Nutrition Journal, 2012, 11, 11.	3.4	47
84	The scopolamine model as a pharmacodynamic marker in early drug development. Psychopharmacology, 2012, 220, 97-107.	3.1	52
85	Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial. PLoS ONE, 2012, 7, e37410.	2.5	201
86	Herbal Cognitive Enhancers: New Developments and Challenges for Therapeutic Applications. , 2012, , 267-289.		1
87	Cognitive performance in relapsing remitting multiple sclerosis: A longitudinal study in daily practice using a brief computerized cognitive battery. BMC Neurology, 2011, 11, 68.	1.8	31
88	The effects of acute tryptophan depletion on neuropsychological function, mood and movement in the healthy elderly. Journal of Psychopharmacology, 2011, 25, 1337-1343.	4.0	8
89	Pharmacodynamic Evaluation: CNS. , 2011, , 423-455.		2
90	Healthy middle-aged individuals are vulnerable to cognitive deficits as a result of increased arterial stiffness. Journal of Hypertension, 2010, 28, 1724-1729.	0.5	57

#	Article	IF	Citations
91	Does a neuropsychological index of hemispheric lateralization predict onset of upper respiratory tract infectious symptoms?. British Journal of Health Psychology, 2010, 15, 469-477.	3.5	7
92	Subtle deficits of attention after surgery: quantifying indicators of sub syndrome delirium. International Journal of Geriatric Psychiatry, 2010, 25, 945-952.	2.7	16
93	Differential effects of the aromas of <i>Salvia</i> species on memory and mood. Human Psychopharmacology, 2010, 25, 388-396.	1.5	63
94	Computerized cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer's disease. Acta Neurologica Scandinavica, 2010, 122, 270-277.	2.1	14
95	Evaluation of techniques to identify beneficial effects of nutrition and natural products on cognitive function. Nutrition Reviews, 2010, 68, S22-S28.	5.8	11
96	Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. Journal of Psychopharmacology, 2010, 24, 1659-1669.	4.0	27
97	Effects of acute tryptophan depletion on neuropsychological and motor function in Parkinson's disease. Journal of Psychopharmacology, 2010, 24, 1465-1472.	4.0	12
98	Evaluation of Dementia Rating Scales in Parkinson's Disease Dementia. American Journal of Alzheimer's Disease and Other Dementias, 2010, 25, 142-148.	1.9	16
99	THE PROFILE OF COGNITIVE IMPAIRMENT IN SCHIZOPHRENIA: IMPLICATIONS FOR THERAPEUTIC TREATMENT STRATEGIES. Schizophrenia Research, 2010, 117, 385-386.	2.0	0
100	Genetic variation of CHRNA4 does not modulate attention in Parkinson's disease. Neuroscience Letters, 2010, 479, 123-125.	2.1	6
101	Coherence training in children with attention-deficit hyperactivity disorder: cognitive functions and behavioral changes. Alternative Therapies in Health and Medicine, 2010, 16, 34-42.	0.0	22
102	Armodafinil for Treatment of Excessive Sleepiness Associated With Shift Work Disorder: A Randomized Controlled Study. Mayo Clinic Proceedings, 2009, 84, 958-972.	3.0	116
103	Approaches to measuring the effects of wakeâ€promoting drugs: a focus on cognitive function. Human Psychopharmacology, 2009, 24, 371-389.	1.5	12
104	The effect of modafinil on cognitive function in breast cancer survivors. Cancer, 2009, 115, 2605-2616.	4.1	156
105	Galantamine-induced improvements in cognitive function are not related to alterations in α4β2 nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]Fluoro-A-85380 PET. Psychopharmacology, 2009, 202, 79-91.	3.1	20
106	The cognitive and psychomotor effects of remacemide and carbamazepine in newly diagnosed epilepsy. Epilepsy and Behavior, 2009, 14, 522-528.	1.7	55
107	Impaired attention predicts falling in Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 110-115.	2.2	179
108	Exploratory pilot study assessing the risk of cognitive impairment or sedation in the elderly following single doses of solifenacin 10 mg. Expert Opinion on Drug Safety, 2009, 8, 615-626.	2.4	79

#	Article	IF	CITATIONS
109	Armodafinil for Treatment of Excessive Sleepiness Associated With Shift Work Disorder: A Randomized Controlled Study. Mayo Clinic Proceedings, 2009, 84, 958-972.	3.0	83
110	An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers. Psychopharmacology, 2008, 198, 127-139.	3.1	129
111	Examining the nootropic effects of a special extract of <i>Bacopa monniera</i> on human cognitive functioning: 90 day doubleâ€blind placeboâ€controlled randomized trial. Phytotherapy Research, 2008, 22, 1629-1634.	5 . 8	116
112	The cognitive effects of modulating the glycine site of the NMDA receptor with highâ€dose glycine in healthy controls. Human Psychopharmacology, 2008, 23, 151-159.	1.5	15
113	Quantifying the association between computerised measures of attention and confusion assessment method defined delirium: a prospective study of older orthopaedic surgical patients, free of dementia. International Journal of Geriatric Psychiatry, 2008, 23, 1253-1260.	2.7	28
114	Candesartan and cognitive decline in older patients with hypertension. Neurology, 2008, 70, 1858-1866.	1.1	103
115	Cognition assessment in paediatric clinical trials. Drug Discovery Today, 2008, 13, 79-85.	6.4	6
116	A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behavioral and Brain Functions, 2008, 4, 24.	3.3	22
117	MODULATION OF COGNITIVE PERFORMANCE AND MOOD BY AROMAS OF PEPPERMINT AND YLANG-YLANG. International Journal of Neuroscience, 2008, 118, 59-77.	1.6	127
118	Cerebral immune activation in chronic hepatitis C infection: A magnetic resonance spectroscopy study. Journal of Hepatology, 2008, 49, 316-322.	3.7	106
119	Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: A 2-[18F]fluoro-A-85380 PET study. Neurobiology of Learning and Memory, 2008, 90, 404-412.	1.9	56
120	Estradiol treatment and its interaction with the cholinergic system: Effects on cognitive function in healthy young women. Hormones and Behavior, 2008, 54, 684-693.	2.1	12
121	The effects of l-theanine, caffeine and their combination on cognition and mood. Biological Psychology, 2008, 77, 113-122.	2.2	210
122	Selective effects of upper respiratory tract infection on cognition, mood and emotion processing: A prospective study. Brain, Behavior, and Immunity, 2008, 22, 399-407.	4.1	60
123	An examination of the effects of the antioxidant Pycnogenol® on cognitive performance, serum lipid profile, endocrinological and oxidative stress biomarkers in an elderly population. Journal of Psychopharmacology, 2008, 22, 553-562.	4.0	103
124	Assessing Change in Cognitive Function in Dementia: The Relative Utilities of the Alzheimer's Disease Assessment Scale – Cognitive Subscale and the Cognitive Drug Research System. Neurodegenerative Diseases, 2008, 5, 261-263.	1.4	33
125	Improvement of cognitive test performance in patients undergoing primary CABG and other CPB-assisted cardiac procedures. Perfusion (United Kingdom), 2008, 23, 267-273.	1.0	16
126	Cognitive Performance and Morning Levels of Salivary Cortisol and \hat{l}_{\pm} -Amylase in Children Reporting High vs. Low Daily Stress Perception. Spanish Journal of Psychology, 2008, 11, 3-15.	2.1	41

#	Article	IF	CITATIONS
127	Effects of Galantamine on Measures of Attention. Alzheimer Disease and Associated Disorders, 2008, 22, 30-38.	1.3	30
128	Effects of Donepezil on Central Processing Speed and Attentional Measures in Parkinson's Disease with Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2007, 23, 161-167.	1.5	51
129	Subtle Attentional Deficits in the Absence of Dementia Are Associated with an Increased Risk of Post-Operative Delirium. Dementia and Geriatric Cognitive Disorders, 2007, 23, 390-394.	1.5	34
130	A low glycaemic index breakfast cereal preferentially prevents children's cognitive performance from declining throughout the morning. Appetite, 2007, 49, 240-244.	3.7	136
131	A double-blind, placebo-controlled, multi-dose evaluation of the acute behavioural effects of guaran \tilde{A}_i in humans. Journal of Psychopharmacology, 2007, 21, 65-70.	4.0	91
132	Dapoxetine Has No Pharmacokinetic or Cognitive Interactions With Ethanol in Healthy Male Volunteers. Journal of Clinical Pharmacology, 2007, 47, 315-322.	2.0	15
133	An open-label study of quetiapine in anorexia nervosa. Human Psychopharmacology, 2007, 22, 223-230.	1.5	29
134	Neuropsychological study of underweight and "weightâ€ecoveredâ€anorexia nervosa compared with bulimia nervosa and normal controls. International Journal of Eating Disorders, 2007, 40, 613-621.	4.0	75
135	Effects of TC-1734 (AZD3480), a selective neuronal nicotinic receptor agonist, on cognitive performance and the EEG of young healthy male volunteers. Psychopharmacology, 2007, 191, 919-929.	3.1	106
136	Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. Drugs of Today, 2007, 43, 349.	1.1	5
137	The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Current Medical Research and Opinion, 2006, 22, 761-774.	1.9	185
138	Expectancy and the aroma of Roman chamomile influence mood and cognition in healthy volunteers. The International Journal of Essential Oil Therapeutics: Exploring the Bioactivity of Aromatic Plants, 2006, 16, 63-73.	0.7	16
139	Effects of Armodafinil in the Treatment of Residual Excessive Sleepiness Associated with Obstructive Sleep Apnea/Hypopnea Syndrome: A 12-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study in nCPAP-Adherent Adults. Clinical Therapeutics, 2006, 28, 689-706.	2.5	131
140	Effects of food on the single-dose pharmacokinetics/pharmacodynamics of tizanidine capsules and tablets in healthy volunteers. Clinical Therapeutics, 2006, 28, 1308-1317.	2.5	19
141	Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. International Journal of Neuropsychopharmacology, 2006, 9, 175.	2.1	126
142	Orthostatic hypotension in Parkinson's disease: association with cognitive decline?. International Journal of Geriatric Psychiatry, 2006, 21, 778-783.	2.7	97
143	Cognitive function testing: the case for standardization and automation. The Journal of the British Menopause Society, 2006, 12, 158-163.	1.3	12
144	A review of cognitive impairment and cerebral metabolite abnormalities in patients with hepatitis C infection. Aids, 2005, 19, S53-S63.	2.2	96

#	Article	IF	CITATIONS
145	Apolipoprotein E ε4 Allele and Lorazepam Effects on Memory in High-Functioning Older Adults. Archives of General Psychiatry, 2005, 62, 209.	12.3	37
146	Pharmacodynamic effects of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder, in healthy volunteers. BJU International, 2005, 96, 1055-1062.	2.5	55
147	Association Between Mild Vascular Cognitive Impairment and Impaired Activities of Daily Living in Older Stroke Survivors Without Dementia. Journal of the American Geriatrics Society, 2005, 53, 103-107.	2.6	75
148	Short-term transdermal estradiol therapy, cognition and depressive symptoms in healthy older women. A randomised placebo controlled pilot cross-over study. Psychoneuroendocrinology, 2005, 30, 309-315.	2.7	54
149	The psychopharmacology of herbal extracts: issues and challenges. Psychopharmacology, 2005, 179, 705-707.	3.1	21
150	Cognitive and mood improvements of caffeine in habitual consumers and habitual non-consumers of caffeine. Psychopharmacology, 2005, 179, 813-825.	3.1	275
151	Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans. Psychopharmacology, 2005, 181, 771-780.	3.1	15
152	Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology, 2005, 65, 1654-1656.	1.1	148
153	Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Current Medical Research and Opinion, 2005, 21, 1423-1429.	1.9	37
154	An automated system for assessing cognitive function in any environment. , 2005, , .		5
155	Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiology and Behavior, 2005, 83, 699-709.	2.1	131
156	ASSESSMENT OF COGNITIVE FUNCTION OF THE ELDERLY POPULATION: EFFECTS OF DARIFENACIN. Journal of Urology, 2005, 173, 493-498.	0.4	169
157	Increased Anticholinergic Challenge-Induced Memory Impairment Associated with the APOE-É>4 Allele in the Elderly: A Controlled Pilot Study. Neuropsychopharmacology, 2004, 29, 403-409.	5.4	38
158	Simultaneous Depletion of Serotonin and Catecholamines Impairs Sustained Attention in Healthy Female Subjects without Affecting Learning and Memory. Journal of Psychopharmacology, 2004, 18, 21-31.	4.0	28
159	Natural products as cognition enhancing agents. , 2004, , 151-178.		3
160	Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2004, 18, 94-100.	1.5	87
161	White Matter Hyperintensities Are Associated With Impairment of Memory, Attention, and Global Cognitive Performance in Older Stroke Patients. Stroke, 2004, 35, 1270-1275.	2.0	118
162	Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome. JAMA - Journal of the American Medical Association, 2004, 292, 1195.	7.4	45

#	Article	IF	CITATIONS
163	Selective Effects of Acute Serotonin and Catecholamine Depletion on Memory in Healthy Women. Journal of Psychopharmacology, 2004, 18, 32-40.	4.0	92
164	Improved cognitive performance in human volunteers following administration of guarana (Paullinia) Tj ETQq0 0 0 Behavior, 2004, 79, 401-411.	rgBT /Ove 2.9	erlock 10 Tf 131
165	Effects of Acute Lorazepam Administration on Aminergic Activity in Normal Elderly Subjects: Relationship to Performance Effects and Apolipoprotein Genotype. Neurochemical Research, 2004, 29, 1391-1398.	3.3	6
166	Baseline Plasma GABA: Its Relationship to the Adverse Effects of Acute Lorazepam Administration on Cognition in the Elderly. Neurochemical Research, 2004, 29, 2311-2315.	3.3	2
167	The effects of protective helmet use on physiology and cognition in young cricketers. Applied Cognitive Psychology, 2004, 18, 1181-1193.	1.6	22
168	Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology, 2004, 63, 2091-2096.	1.1	267
169	Reliable diagnoses of dementia by the naive credal classifier inferred from incomplete cognitive data. Artificial Intelligence in Medicine, 2003, 29, 61-79.	6.5	60
170	Carotid Endarterectomy Improves Cognitive Function in Patients with Exhausted Cerebrovascular Reserve. European Journal of Vascular and Endovascular Surgery, 2003, 26, 529-536.	1.5	78
171	Salvia lavandulaefolia (Spanish Sage) enhances memory in healthy young volunteers. Pharmacology Biochemistry and Behavior, 2003, 75, 669-674.	2.9	151
172	AROMAS OF ROSEMARY AND LAVENDER ESSENTIAL OILS DIFFERENTIALLY AFFECT COGNITION AND MOOD IN HEALTHY ADULTS. International Journal of Neuroscience, 2003, 113, 15-38.	1.6	330
173	Breakfast reduces declines in attention and memory over the morning in schoolchildren. Appetite, 2003, 41, 329-331.	3.7	223
174	Modulation of Mood and Cognitive Performance Following Acute Administration of Single Doses of Melissa Officinalis (Lemon Balm) with Human CNS Nicotinic and Muscarinic Receptor-Binding Properties. Neuropsychopharmacology, 2003, 28, 1871-1881.	5.4	161
175	Safety, Pharmacokinetics, and Effects on Cognitive Function of Multiple Doses of GTS-21 in Healthy, Male Volunteers. Neuropsychopharmacology, 2003, 28, 542-551.	5.4	222
176	Effects of Hypertension on Attention, Memory, and Executive Function in Older Adults Health Psychology, 2003, 22, 587-591.	1.6	97
177	Mild Cognitive Impairment and Vascular Cognitive Impairment in Stroke Patients. International Psychogeriatrics, 2003, 15, 123-126.	1.0	11
178	Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics and Genomics, 2003, 13, 231-239.	5.7	85
179	Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology, 2003, 18, 9-14.	1.7	86
180	Reboxetine versus paroxetine versus placebo: effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology, 2003, 18, 9-14.	1.7	21

#	Article	IF	CITATIONS
181	The evaluation of cognitive function in the dementias: methodological and regulatory considerations. Dialogues in Clinical Neuroscience, 2003, 5, 77-88.	3.7	18
182	A randomised crossover trial of post-operative cognitive and psychomotor recovery from benzodiazepine sedation: effects of reversal with flumazenil over a prolonged recovery period. British Dental Journal, 2002, 192, 335-339.	0.6	21
183	Validation of a telephone cognitive assessment test battery for use in chronic fatigue syndrome. Journal of Telemedicine and Telecare, 2002, 8, 337-343.	2.7	7
184	Effects of Rivastigmine on Cognitive Function in Dementia with Lewy Bodies: A Randomised Placebo-Controlled International Study Using the Cognitive Drug Research Computerised Assessment System. Dementia and Geriatric Cognitive Disorders, 2002, 13, 183-192.	1.5	173
185	The effect of glucose administration and the emotional content of words on heart rate and memory. Journal of Psychopharmacology, 2002, 16, 241-244.	4.0	23
186	Apolipoprotein E Îμ4 and short-term recovery from predominantly mild brain injury. Neurology, 2002, 58, 1038-1044.	1.1	125
187	Basal activity of the HPA axis and cognitive function in anorexia nervosa. International Journal of Neuropsychopharmacology, 2002, 5, 17-25.	2.1	27
188	Chewing gum selectively improves aspects of memory in healthy volunteers. Appetite, 2002, 38, 235-236.	3.7	130
189	Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiology and Behavior, 2002, 75, 739-751.	2.1	138
190	Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacology Biochemistry and Behavior, 2002, 72, 953-964.	2.9	203
191	Practice effects on cognitive tasks: a major problem?. Lancet Neurology, The, 2002, 1, 473.	10.2	80
192	A Pharmacokinetic and Pharmacodynamic Drug Interaction Study of Acamprosate and Naltrexone. Neuropsychopharmacology, 2002, 27, 596-606.	5.4	99
193	Assessing cognitive function in clinical trials: latest developments and future directions. Drug Discovery Today, 2002, 7, 29-35.	6.4	18
194	The acute nootropic effects of Ginkgo biloba in healthy older human subjects: a preliminary investigation. Human Psychopharmacology, 2002, 17, 45-49.	1.5	28
195	The acute effects of combined administration of Ginkgo biloba and Bacopa monniera on cognitive function in humans. Human Psychopharmacology, 2002, 17, 163-164.	1.5	14
196	A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil. Anaesthesia, 2002, 57, 868-876.	3.8	20
197	Neuropsychological Deficits in Older Stroke Patients. Annals of the New York Academy of Sciences, 2002, 977, 179-182.	3.8	21
198	Cognitive Associations of Subcortical White Matter Lesions in Older People. Annals of the New York Academy of Sciences, 2002, 977, 436-444.	3.8	115

#	Article	IF	CITATIONS
199	Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology, 2002, 35, 433-439.	7.3	407
200	Water ingestion improves subjective alertness, but has no effect on cognitive performance in dehydrated healthy young volunteers. Appetite, 2001, 37, 255-256.	3.7	58
201	The use of cognitive tests to facilitate drug and dose selection in Phase I and to optimise dosing in Phase IV. International Congress Series, 2001, 1220, 35-50.	0.2	7
202	Differential, Dose Dependent Changes in Cognitive Performance Following Acute Administration of a <i>Ginkgo biloba/Panax ginseng</i> Combination to Healthy Young Volunteers. Nutritional Neuroscience, 2001, 4, 399-412.	3.1	96
203	Dose Dependent Changes in Cognitive Performance and Mood following Acute Administration of Ginsengto Healthy Young Volunteers. Nutritional Neuroscience, 2001, 4, 295-310.	3.1	119
204	Cerebral injury during cardiopulmonary bypass: Emboli impair memory. Journal of Thoracic and Cardiovascular Surgery, 2001, 121, 1150-1160.	0.8	164
205	Credal Classification for Dementia Screening. Lecture Notes in Computer Science, 2001, , 67-76.	1.3	1
206	The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. British Journal of Psychiatry, 2000, 177, 252-256.	2.8	319
207	Quantification and Characterisation of Fluctuating Cognition in Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2000, 11, 327-335.	1.5	77
208	Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. British Journal of Clinical Pharmacology, 2000, 49, 110-117.	2.4	34
209	The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology, 2000, 151, 416-423.	3.1	240
210	The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology, 2000, 152, 353-361.	3.1	281
211	Cognitive Performance in Hypertensive and Normotensive Older Subjects. Hypertension, 2000, 36, 1079-1082.	2.7	168
212	The acute effects of amisulpride (50 mg and 200 mg) and haloperidol (2 mg) on cognitive function in healthy elderly volunteers. Journal of Psychopharmacology, 2000, 14, 164-171.	4.0	40
213	The cognitive and psychomotor effects of morphine in healthy subjects: a randomized controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain, 2000, 85, 209-215.	4.2	57
214	Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet, The, 2000, 356, 2031-2036.	13.7	1,138
215	The value of assessing cognitive function in drug development. Dialogues in Clinical Neuroscience, 2000, 2, 183-202.	3.7	22
216	A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. Journal of Psychopharmacology, 1999, 13, 152-158.	4.0	77

#	Article	IF	Citations
217	A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease. Human Psychopharmacology, 1999, 14, 239-245.	1.5	9
218	Cognitive Performance, Hyperoxia, and Heart Rate Following Oxygen Administration in Healthy Young Adults. Physiology and Behavior, 1999, 67, 783-789.	2.1	127
219	Cognitive properties of sedation agents: comparison of the effects of nitrous oxide and midazolam on memory and mood. British Dental Journal, 1999, 187, 557-562.	0.6	9
220	Relationships among age, conditioned stimulus–unconditioned stimulus interval, and neuropsychological test performance Neuropsychology, 1999, 13, 90-102.	1.3	23
221	Relationships among age, conditioned stimulus-unconditioned stimulus interval, and neuropsychological test performance Neuropsychology, 1999, 13, 90-102.	1.3	11
222	Effects of physostigmine on scopolamine-induced changes in quantitative electroencephalogram and cognitive performance., 1998, 13, 199-210.		22
223	Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: a 6-year follow-up., 1998, 13, 244-247.		10
224	Oxygen administration selectively enhances cognitive performance in healthy young adults: a placebo-controlled double-blind crossover study. Psychopharmacology, 1998, 138, 27-33.	3.1	106
225	Oxygen and cognitive performance: the temporal relationship between hyperoxia and enhanced memory. Psychopharmacology, 1998, 140, 123-126.	3.1	52
226	Validity of a cognitive computerized assessment system in brain injured patients. Brain Injury, 1998, 12, 1037-1043.	1.2	65
227	Cognitive performance in recreational users of MDMA or 'ecstasy': evidence for memory deficits. Journal of Psychopharmacology, 1998, 12, 79-83.	4.0	208
228	Tiagabine: Absence of Kinetic or Dynamic Interactions with Ethanol. Drug Metabolism and Drug Interactions, 1998, 14, 259-73.	0.3	15
229	Pharmacokinetics and Pharmacodynamics of Scopolamine after Subcutaneous Administration. Journal of Clinical Pharmacology, 1998, 38, 720-726.	2.0	84
230	The effect of a 50 Hz magnetic field on cognitive function in humans. International Journal of Radiation Biology, 1998, 74, 463-470.	1.8	61
231	BRIDGING STUDY OF S12024 IN 53 INâ€PATIENTS WITH ALZHEIMER'S DISEASE. Journal of the American Geriatrics Society, 1997, 45, 125-126.	2.6	23
232	Moxonidine and cognitive function: interactions with moclobemide and lorazepam. European Journal of Clinical Pharmacology, 1997, 52, 351-358.	1.9	33
233	Cognitive performance and mood after a weekend on call in a surgical unit. British Journal of Surgery, 1997, 84, 493-495.	0.3	91
234	The cognitive, subjective, and physical effects of a ginkgo biloba/panax ginseng combination in healthy volunteers with neurasthenic complaints. Psychopharmacology Bulletin, 1997, 33, 677-83.	0.0	42

#	Article	IF	CITATIONS
235	Cigarette Smoking and Abstinence: Comparative Effects Upon Cognitive Task Performance and Mood State over 24 Hours. Human Psychopharmacology, 1996, 11, 391-400.	1.5	92
236	Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men*. Clinical Pharmacology and Therapeutics, 1996, 59, 675-685.	4.7	7
237	Cognitive and Quantified Electroencephalographic Correlates of Cycloserine Treatment in Alzheimer's Disease. Clinical Neuropharmacology, 1995, 18, 28-38.	0.7	22
238	The cognitive drug research computerized assessment system in the evaluation of early dementia-is speed of the essence? International Journal of Geriatric Psychiatry, 1995, 10, 199-206.	2.7	47
239	Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers. International Journal of Geriatric Psychiatry, 1995, 10, 1059-1062.	2.7	9
240	The cognitive and psychomotor effects of opioid analgesics. European Journal of Clinical Pharmacology, 1995, 48, 447-53.	1.9	36
241	The cognitive and psychomotor effects of opioid analgesics. European Journal of Clinical Pharmacology, 1995, 48, 455-60.	1.9	80
242	A pilot study of the effect of low level exposure to mercury on the health of dental surgeons Occupational and Environmental Medicine, 1995, 52, 813-817.	2.8	22
243	Single dose human pharmacology of umespirone. European Journal of Clinical Pharmacology, 1994, 46, 461-8.	1.9	24
244	Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clinical Pharmacology and Therapeutics, 1992, 52, 427-435.	4.7	51
245	Cholinesterase Inhibition in the Scopolamine Model of Dementia. Annals of the New York Academy of Sciences, 1991, 640, 268-271.	3.8	55
246	Effects of NMDA Modulation in Scopolamine Dementiaa. Annals of the New York Academy of Sciences, 1991, 640, 241-244.	3.8	77
247	The cognitive drug research computerized assessment system for demented patients: A validation study. International Journal of Geriatric Psychiatry, 1991, 6, 95-102.	2.7	172
248	A double-blind, placebo controlled study of Ginkgo biloba extract ( Tanakan') in elderly outpatients with mild to moderate memory impairment. Current Medical Research and Opinion, 1991, 12, 350-355.	1.9	139
249	The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Journal of Psychopharmacology, 1990, 4, 219-232.	4.0	31
250	Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. Advances in Neurology, 1990, 51, 261-8.	0.8	15
251	EFFECTS OF TEMAZEPAM PREMEDICATION ON COGNITIVE RECOVERY FOLLOWING ALFENTANIL—PROPOFOL ANAESTHESIA. British Journal of Anaesthesia, 1989, 63, 68-75.	3.4	23
252	The effects of moclobemide on cognition. Journal of Neural Transmission Supplementum, 1989, 28, 91-102.	0.5	18

#	Article	IF	CITATIONS
253	An investigation of the range of cognitive impairments induced by scopolamine 0Â-6 mg s.c. Human Psychopharmacology, 1988, 3, 27-41.	1.5	99
254	Promethazine, scopolamine and cinnarizine: comparative time course of psychological performance effects. Psychopharmacology, 1987, 92, 513-9.	3.1	27
255	A double-blind placebo-controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. Human Psychopharmacology, 1987, 2, 159-169.	1.5	98
256	Nicotine Increases Mental Efficiency: But How?. Advances in Behavioral Biology, 1987, , 63-79.	0.2	18
257	Effects of Temazepam on Sleep Quality and Subsequent Mental Efficiency under Normal Sleeping Conditions and following Delayed Sleep Onset. Neuropsychobiology, 1986, 15, 187-191.	1.9	7
258	Facilitation of learning and state dependency with nicotine. Psychopharmacology, 1986, 89, 55-9.	3.1	90
259	Scopolamine and the Sensory Conditioning of Hallucinations. Neuropsychobiology, 1985, 14, 198-202.	1.9	21
260	Smoking as a coping strategy. Addictive Behaviors, 1985, 10, 209-224.	3.0	55
261	Evidence of more rapid stimulus evaluation following cigarette smoking. Addictive Behaviors, 1985, 10, 113-126.	3.0	110
262	Historical Overview of Research on Cholinergic Systems and Behavior., 1985,, 1-35.		3
262	Historical Overview of Research on Cholinergic Systems and Behavior. , 1985, , 1-35. Acetylcholine and Attentional Disorder. , 1985, , 223-245.		3
		3.1	
263	Acetylcholine and Attentional Disorder. , 1985, , 223-245. The effects of cigarettes of varying yield on rapid information processing performance.	3.1	2
263	Acetylcholine and Attentional Disorder., 1985,, 223-245. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology, 1984, 82, 338-342. Effects of scopolamine and nicotine on human rapid information processing performance.		110
263 264 265	Acetylcholine and Attentional Disorder., 1985,, 223-245. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology, 1984, 82, 338-342. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology, 1984, 82, 147-150. The separate and combined effects of scopolamine and nicotine on human information processing.	3.1	2 110 355
263 264 265 266	Acetylcholine and Attentional Disorder., 1985, , 223-245. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology, 1984, 82, 338-342. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology, 1984, 82, 147-150. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology, 1984, 84, 5-11. Effects of Smoking on Rapid Information Processing Performance. Neuropsychobiology, 1983, 9,	3.1	2 110 355 140
264 265 266 267	Acetylcholine and Attentional Disorder., 1985,, 223-245. The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology, 1984, 82, 338-342. Effects of scopolamine and nicotine on human rapid information processing performance. Psychopharmacology, 1984, 82, 147-150. The separate and combined effects of scopolamine and nicotine on human information processing. Psychopharmacology, 1984, 84, 5-11. Effects of Smoking on Rapid Information Processing Performance. Neuropsychobiology, 1983, 9, 223-229.	3.1 3.1 1.9	2 110 355 140 214